The 15th Asia-Pacific Cochlear Implant and Related Scientific Conference (APSCI 2025) recently concluded successfully in Kuala Lumpur, Malaysia. This conference brought together over a thousand hearing medicine experts, researchers, and industry representatives from dozens of countries and regions worldwide to discuss the latest advancements and clinical practices in cochlear implant technology. Nurotron, as a leading company in China’s cochlear implant field, actively participated and showcased numerous cutting-edge research findings and clinical strengths.
Live Surgery Performance Impresses Audience, Precise Operation Demonstrates Chinese Technology
During the conference, Prof. Jun LIU, Director of the Department of Otolaryngology at Henan Provincial People’s Hospital, conducted a high-level live surgical demonstration. He skillfully implanted the Nurotron CS-20A cochlear implant into a patient, with Prof. Jianxin QIU, Director of The First Affiliated Hospital of Anhui Medical University, assisting him. Afterwards, Prof. Li YIN, Executive Vice President and Chief Medical Officer of Nurotron, explained and introduced Nurotron’s electrodes. This live broadcast not only showcased Prof. Jun LIU’s superb surgical skills but also visually demonstrated the excellent performance and reliability of the Nurotron implant to international colleagues, garnering widespread attention and praise from the audience.
Prof. Jun LIU was demonstrating surgery
Second from right: Prof. Jianxin QIU
Prof. Li YIN was introducing Nurotron electrodes
From left to right: Nurotron CEO Mr. Chu LI, Prof. Jun LIU, Chairman of APSCI 2025 Prof. Tang, Prof. Jianxin QIU, Prof. Li YIN, Mr. Jose Carlos Canadas
Multiple Research Findings Released, Deep Scientific Research Gains International Recognition
In addition to the impressive surgical demonstrations, the Nurotron team and collaborating experts released a series of groundbreaking research reports at the conference. Nurotron had a total of six oral presentations and two poster presentations selected, fully demonstrating the company’s profound expertise in both basic and clinical research:
Prof. Jun LIU discussed in depth “Effects of the Number of Channels on Speech Recognition in Chinese Cochlear Implant Recipients” in his report. Research results indicate that as the number of channels increases to 24, patients’ speech recognition ability in quiet environments is further improved, providing important evidence for product optimization.
Prof. Haiqiao DU of The Sixth Medical Center of PLA General Hospital presented a 15-year follow-up study, ” A 15-year in-depth follow-up of post-lingual hearing loss patients with Chinese domestic cochlear implants” providing detailed data to demonstrate the long-term safety, effectiveness, and stability of the Nurotron “Morning Star” system.
Prof. Li YIN, Executive Vice President and Chief Medical Officer of Nurotron, shared ” Electrophysiological characteristics, parameter optimization, and clinical application of electrically evoked auditory brainstem responses after cochlear implantation” providing clear guidance for the clinical application of EABR, an important objective assessment tool.
Ms. Shanxian GAO, Administrative Vice President of the Audiology, Speech & Medical Reserach Institute, shared two studies: ” Restoration of deafferentation reduces tinnitus, anxiety, and depression: a retrospective study on cochlear implant patients” indicating that continuous use of the cochlear implant (CI) can effectively alleviate tinnitus and related mental symptoms; and ” Impact of Age on Electrode-Neuron Interface Quality and Postoperative Programing in Cochlear Implant Recipients” revealing the impact of aging on electrode-neural interface quality and providing guidance for personalized postoperative rehabilitation.
Clinical Research Specialist Mr. Tianyi LIU introduced the “The Development and Validation of the Quick Self-Assessment Questionnaire for Cochlear Implant Outcome (QSACI)” a tool that helps predict implantation outcomes preoperatively and helps patients establish reasonable expectations.
Enthusiastic Interaction at the Booth; Domestic Innovation Highly Favored
During the conference, the Nurotron booth was consistently bustling with visitors. Experts, clinicians, and industry partners from the Asia-Pacific region and around the world stopped to learn more about Nurotron’s full range of cochlear implant products. Attendees showed great interest in the product’s superior performance, clear sound quality, and user-friendly design. The atmosphere of interaction and exchange was lively, fully demonstrating Nurotron’s market popularity and international influence as a leading domestic high-end medical technology brand.
This trip to APSCI 2025 not only earned Nurotron the respect of international peers through its solid clinical technology and cutting-edge research achievements, but also reaffirmed China’s innovative strength in the field of high-end medical devices. In the future, Nurotron will continue to uphold its mission of ” Help the hearing impaired hear” helping more hearing-impaired people around the world regain their voices and return to the world of sound.
